CD22 and leukemia: With anti-CD22 CAR-T cell therapy, a simple quantitative reduction in CD22 expression or density in the leukemic population was sufficient to avoid CAR-T cells, thereby allowing leukemia relapse despite persistent CD22 positivity, with individual differences in threshold antigen density that were responsible for relapse or resistance [178].